HER2-positive breast cancer accounts for approximately 15% of all breast cancer diagnoses and it is characterized by a poor prognosis in the absence of specific HER2-targeting therapies [[3], [4], [5]]. The gene discussed is ERBB2; the disease is breast carcinoma.